Gefitinib and erlotinib, two FDA-approved EGFR inhibitors used in the treatment of non-small-cell lung carcinoma (NSCLC), individually inhibited U-CH1, U-CH7, UM-Ch-SCor1, and MUG-Chor1 cellular proliferation in dose-dependent manners20,34. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.